论文部分内容阅读
目的:探讨结直肠癌患者血清中sFas和组织中FasL表达与术后肝转移的关系。方法:采用ELISA法测定60例结直肠癌患者术前血清中sFas水平,同时采用免疫组化SP法检测该60例结直肠癌患者术后标本FasL的表达。结果:26例肝转移组中sFas水平为(25.32±4.24)ng/mL,34例非肝转移组中sFas水平为(12.22±2.58)ng/mL,两组间差异有统计学意义,P=0.004;肝转移组中FasL阳性表达率为84.6%(22/26),而非肝转移组中FasL阳性表达率为47.1%(16/34),两组差异有统计学意义,P=0.003。结论:结直肠癌患者血清sFas和组织FasL表达可能与结直肠癌术后肝转移呈正相关。
Objective: To investigate the relationship between the expression of sFas in serum and the expression of FasL and the postoperative liver metastasis in patients with colorectal cancer. Methods: The serum levels of sFas in 60 patients with colorectal cancer were detected by ELISA. The expression of FasL in 60 patients with colorectal cancer was detected by immunohistochemical SP method. Results: The sFas level was (25.32 ± 4.24) ng / mL in 26 liver metastases and (12.22 ± 2.58) ng / mL in 34 non-hepatic metastases, with significant difference between the two groups (P = 0.004. The positive rate of FasL in liver metastasis was 84.6% (22/26), while the positive rate of FasL in non-liver metastasis was 47.1% (16/34). There was significant difference between the two groups (P = 0.003). Conclusion: The expression of sFas and FasL in colorectal cancer patients may be positively correlated with postoperative liver metastasis of colorectal cancer.